ArticleDiscover oncology2025
A decade of scientific advancements and collaborations on CRISPR-Cas9 application in cancer research: a bibliometric review.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The CRISPR-Cas system, a novel gene-editing technique, was a focus of research on cancer diagnosis and treatment during the last decade. A systematic review of the research trends and collaborations of the literature published in PubMed database between 2014 and 2024 resulted in 3241 papers. Bibliometric analysis and data visualization were performed using Excel, RStudio, and VOSviewer software. An increasing trend in the number of publications and citations has been observed since 2014, with a moderate fall after 2023. China and the USA have contributed the most publications and international collaborations, and high-income nations involved the highest contributions in the literature. The most productive institutes were Harvard Medical School and Dana-Farber Cancer Institute. Wang and Li contributed the maximum number of publications in this field. The prominent sources were Cancer Research, and Cancers. The application of CRISPR technique in breast and colorectal cancers has been frequently studied during the last decade. Future trials should explore the specificity and safety of CRISPR in various cancers.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.